Register
Login:
Share:
Email Facebook Twitter




ShareCast News - Broker Recommendations





Investec affirms 'buy' rating for BTG, confident about varicose vein treatment

Investec reiterated a 'buy' rating and price target of 647p for pharmaceuticals firm BTG after reappraising its key product Varithena.
[1 Hour Ago]

RBC starts Close Brothers at 'sector perform'

RBC Capital Markets initiated coverage of Close Brothers at 'sector perform' with a 1,600p price target.
[3 Hours Ago]

Nomura mulls possible scenarios in Greek debt drama

As Greece edged ever closer to defaulting on its debt repayment to the International Monetary Fund, Nomura took a look at how the saga could pan out, dividing the possible outcomes into market friendly' and 'market unfriendly' scenarios.
[5 Hours Ago]

Broker Tips: Brewin Dolphin, Wentworth, United Utilities

RBC Capital Markets upgraded Brewin Dolphin to 'outperform' from 'sector perform' and kept the price target unchanged at 335p.
[5 Hours Ago]

Panmure retains 'buy' rating on Wentworth, slashes target price

Panmure Gordon has kept a 'buy' rating on Wentworth Resources and reduced its target price, citing a reduced production profile.
[6 Hours Ago]

HSBC upgrades United Utilities to 'buy'

HSBC upgraded United Utilities to 'buy' from 'hold' and bumped up its price target to 1,050p from 1,000p.
[6 Hours Ago]

RBC Capital Markets upgrades Brewin Dolphin to 'outperform'

RBC Capital Markets upgraded Brewin Dolphin to 'outperform' from 'sector perform' and kept the price target unchanged at 335p.
[7 Hours Ago]

Broker tips: GlaxoSmithKline, Astrazeneca, Hikma, Shire, Petrofac, ARM Holdings

HSBC initiated coverage of the European pharmaceuticals, saying the re-rating over the last few years looks set to continue.
[Fri 11:39]

Morgan Stanley sets new mid 2016 target range for Shanghai Composite

Morgan Stanley set a new mid 2016 target range for the Shanghai Composite of 3,250-4,600, down from its prior end-2015 target range of 4,000-4,800, and below the current level of the index.
[Fri 11:07]

Liberum upgrades GlaxoSmithKline to 'hold'

Liberum upgraded GlaxoSmithKline to 'hold' from 'sell', but cut the price target to 1,350p from 1,400p.
[Fri 10:33]



Categories: AIM Bulletin, Broker Recommendations, Commodities, Company News, Dealings and Holdings, Economic News, Foreign Exchange, International News, Market Report, New Issues, News and Announcements, Press Round-Up, Risers and Fallers, Small Cap News, Technical Analysis, Tips Round-Up, Week Ahead.


Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.